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robust standard errors, and applied baseline sampling weights to
obtain estimates representative for the entire US population with
MS. For provider visits and amount of personal care (conditional
on using it), we estimated similar GLS Gaussian models with
logarithmic transformation of the number of services as depen-
dent variable. RESULTS: Use of most medical services increased
signiﬁcantly with the worsening of MS. However, patients with
severe MS (EDSS > 7.0) used the same or fewer services than
patients with EDSS 6.5–7 except for home health and personal
care. Having relapses signiﬁcantly increased use of most catego-
ries of health services. Longer time since diagnosis, after adjust-
ing for MS stage, was associated with a lower level of utilization
of ER, hospital outpatient care, therapy, and alternative medi-
cine. Patients who were not married generally used more services
than married patients. CONCLUSION: While MS places a sub-
stantial ﬁnancial burden on individuals as well as private and
public payers, use of speciﬁc categories of health services varies
signiﬁcantly with MS severity, presence of relapses, and availabil-
ity of informal help.
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OBJECTIVE: The population over 60 years old is increasing in
Mexico, and thus, the prevalence of chronic-degenerative dis-
eases such as the Parkinson’s Disease is increasing. The objective
of this study was to compare the cost-utility of the treatment with
pramipexol vs. the treatment with l-dopa/carbidopa and sus-
tained release l-dopa/carbidopa, from an institutional perspective
in Mexico. METHODS: A cost-utility analysis was performed
using a decision tree model that simulates the cost and Quality
Adjusted Life Years (QALYs) for a hypothetical cohort of
patients recently diagnosed with Parkinson’s Disease, consider-
ing development or not of dyskinesias throughout a temporary
horizon of four years. The utilities for each health state were
obtained from reports in international literature. The model also
considers changes in drug’s dosage or the possibility that the
patient received treatment with both drugs, according to the
response and associated adverse events. Only annual costs per
drug were considered for this analysis, as the rest of the costs are
similar for buyers. Costs were estimated using 2006 prices and
are expressed in US dollars (exchange rate of 10.9 pesos per US
dollar). RESULTS: It was estimated that a patient treated with
pramipexol would have 3.07 QALYs on average vs. 1.96 QALYs
for a patient treated with L-DOPA/carbidopa, and 1.98 QALYs
for sustained release L-DOPA/carbidopa. Annual costs associ-
ated with each treatment are $1177.50 for pramipexol, $225.60
for L-DOPA/carbidopa and $449.90 for sustained release
L-DOPA/carbidopa. The incremental cost per QALY gained was
$3441.70 for pramipexol vs. l-dopa/carbidopa and $2649.8 for
pramipexol compared with sustained release l-dopa/carbidopa.
CONCLUSION: In Mexico, the treatment with pramipexol is a
highly cost-effective alternative to manage Parkinson’s disease
considering the WHO cost-effectiveness threshold of 1GDP.
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OBJECTIVE: Compare annual indirect costs between privately
insured USA employees with multiple sclerosis (MS) and
matched employee controls. METHODS: Employees with 1
MS diagnosis (ICD-9-CM: 340.x) after January 1, 2002, ages
18–64 years, were selected from a privately insured claims data-
base containing disability data from 17 USA companies. Employ-
ees with MS were matched by age and gender to employee
controls without MS. All were required to have continuous
health coverage 3 months before MS diagnosis (baseline) and 12
months after (study period). Chi-squared tests were used to
compare baseline comorbidities and differences in indirect
resource use (disability and medically-related absenteeism). Wil-
coxon rank-sum tests were used for univariate comparisons of
mean disability and medically-related absenteeism days and asso-
ciated annual indirect costs during the study period. RESULTS:
Employees with MS (n = 989) averaged 44 years old, and 66%
were female. Compared with employee controls, employees with
MS had signiﬁcantly higher rates of mental health disorders and
other neurological disorders and physical disorders as measured
by the Charlson Comorbidity Index. Employees with MS were
more likely to have short-term or long-term disability compared
to employee controls (21.4% vs 5.2%, respectively; P < 0.0001),
resulting in a higher mean number of disability days per year
(29.8 vs 4.5, respectively, P < 0.0001). Employees with MS also
had a higher rate of medically-related absenteeism and associated
absenteeism days compared to employee controls. On average,
annual costs for disability were signiﬁcantly higher for employees
with MS ($3868) compared with employee controls ($414);
P < 0.0001. Medically-related absenteeism costs were also higher
for employees with MS compared with controls ($1901 vs
$1003, respectively; P < 0.0001). On average, total indirect
costs for employees with MS was $5769 compared with con-
trols, $1417 (P < 0.0001). CONCLUSION: Indirect costs of
employees with MS were >4 times those of employee controls.
Effective treatments may reduce the burden of this disease in the
workplace.
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OBJECTIVE: Migraines afﬂict about 30 million people in the
United States. Determining how migraineurs differ from non-
migraneurs from the viewpoint of health resource utilization may
provide insights that could lead to more effective care strategies.
The objective of this study is to compare resource utilization
between migraineurs and non-migraineurs. METHODS: Care-
mark administrative pharmacy and medical claims data were
analyzed in this study over a one year period. Individuals with at
least one migraine medical claim (ICD-9 of 346.xx) and one
triptan/ergot claim were used to identify participants with
Migraine. Propensity score matching was used to sample partici-
pants without migraine (controls) matched for age, gender, and
number of co-morbidities. Outcomes included number of visits
and expenditures associated with ofﬁce visits (MD), emergency
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room visits (ER), hospitalizations (HOS) using medical claims
data, and prescription costs (Rx) using pharmacy claims data.
Analysis of covariance was used to determine differences in
health care use and expenditures, adjusting for age, gender, and
number of co-morbidities. RESULTS: There were 13,796 partici-
pants in the analysis. Baseline characteristics (age, gender, and
number of co-morbidities) were comparable in the two groups
after matching. Eighty percent of migraine participants identiﬁed
were female. Analyses involving the complete models showed
that migraineurs incurred signiﬁcantly higher expenditure than
non-migraineurs. After adjusting for age, sex and number of
co-morbidities, migraineurs had signiﬁcantly more ER visits per
year (0.7 vs. 0.2, p < 0.0001). Annual ER, HOS, and Total
expenditures were signiﬁcantly higher in the Migraine cohort
(ER: $480 vs. $125, p < 0.0001 and HOS: $980 vs. $588,
p < 0.00001 and Total: $4233 vs. $2004, p < 0.0001). CON-
CLUSION: Migraine patients utilize more health care resources
and incur higher health care expenditures. Study ﬁndings high-
light the beneﬁts to be realized by managing individuals with
migraine.
NEUROLOGICAL DISORDERS—
Patient-Reported Outcomes
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OBJECTIVE: Medication non-adherence among patients with
chronic conditions can have both clinical and economic conse-
quences. The objective is to investigate whether non-adherence to
antiepileptic drugs (AEDs) is associated with increased morbidity
relative to adherence, as proxied by health care utilization and
costs, in a Medicaid population with epilepsy. METHODS: A
retrospective open-cohort design using state Medicaid claims
data from Florida, Iowa and New Jersey in the period of January
1997–June 2006 was employed. Patients aged 18 with 1
diagnosis of epilepsy, 1 neurologist visit, 2 AED dispensings,
and 6 months of baseline period were included. Medication
possession ratio (MPR) was used to evaluate AED adherence on
a quarterly basis with MPR 0.8 considered adherent and <0.8
non-adherent. The association of non-adherence with health
care utilization was assessed using univariate and multivariate
Poisson regressions to model frequency of hospitalizations, inpa-
tient days, emergency room (ER), and outpatient visits per
person-year of observation. Quarterly per-patient inpatient, out-
patient, ER, and pharmacy costs were calculated across non-
adherent and adherent quarters for the under-65 population and
cost differences computed. Adjusted incremental costs of non-
adherence were estimated with multivariate Tobit regression
models. RESULTS: A total of 33,658 patients met the study
inclusion criteria (28,470 under-65), together contributing
388,564 (74%) adherent and 136,550 (26%) non-adherent quar-
ters. Non-adherence was associated with signiﬁcantly higher
incidence of hospitalizations (incidence rate ratio [IRR] = 1.39,
95% conﬁdence interval [CI] = 1.37–1.41), inpatient days
(IRR = 1.76, 95% CI = 1.75–1.78), and ER visits (IRR = 1.19.
95% CI = 1.18–1.21). Non-adherence was associated with posi-
tive quarterly incremental costs related to serious outcomes,
including inpatient ($4320, 95% CI = $4077–$4564) and ER
($303, 95% CI = $273–$334) services. CONCLUSION: Non-
adherence to AEDs is relatively common and appears to be
associated with increased morbidity as represented by higher
health care utilization and costs.
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OBJECTIVE: Our study explores the relationship between
30-day and 90-day pharmacy dispensing systems and patient
medication compliance, persistency, and ﬁnancial incentive.
METHODS: Retrospective pharmacy claims data of multiple
sclerosis (MS) patients using four different medications were
extracted from a pharmacy database. Patients were followed
one year. Compliance was measured using the medication pos-
session ratio (MPR), calculated using the ISPOR method. Anni-
versary method and Kaplan-Meier survival curves were applied
to describe patients’ persistency. Associations with drop-off and
different systems were assessed using Cox regression model.
Wilcoxon-Mann-Whitney test was used to compare the mean
patient out-of-pocket and payers’ costs for two systems.
RESULTS: Study sample consisted of 29,808 eligible MS
patients predominantly female (77.01%), mean age of 48.4
years. Therapy-speciﬁc MPRs on the 30-day and the 90-day
system, respectively, were 89.39% and 93.77% with a hazard
ratio (HR) for drop-off of 1.657 for Interferon beta-1a
(Avonex), 82.72% vs. 88.92% (HR = 1.486) for Interferon
beta-1b, 81.48% vs. 88.21% (HR = 1.480) for glatiramer
acetate and 87.46% vs. 90.73% (HR = 1.606) for Interferon
beta-1a (Rebif). Overall MPR comparison between 30-day and
90-day was 85.55% vs. 90.79% (HR = 1.557). Cost per dose
for patients out-of-pocket and payers for a 30-day supply was
$70.78 and $1402.10, respectively. In contrast, a 90-day supply
was $30.59 and $1404.70, respectively. Signiﬁcance tests
showed the comparison was statistically signiﬁcant at level
0.05, except comparison between payer’s costs with a p-value
of 0.46. CONCLUSION: MS patients using 90-day have higher
MPR than patients using 30-day. The patients using 30-day are
more likely to drop off, with a 55.7% higher risk of discon-
tinuation. Results suggest that providing a 90-day supply
improves MS patients’ compliance and persistency within the
one-year study period. Patients spend less when using 90-day
system. Future study focuses on pharmacoeconomic impact of
the dispensing system, incorporating outcome variables for MS
patients’ quality of life.
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OBJECTIVE: To examine compliance rates, measured with the
medication possession ratio (MPR) and 12-month persistence
rates of patients initiating 1 of 4 immunomodulating treatments
for multiple sclerosis (MS). METHODS: The study population
consisted of patients aged 18–64 years initiating MS treatment
from January 2, 2004, to July 5, 2005. Patients were identiﬁed
from an administrative claims database (PharMetrics, Inc.,
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